Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany.
Division of Paediatric Infectious Diseases, Dr. von Hauner Children's Hospital, Ludwig Maximilians University, 80337 Munich, Germany.
Cells. 2020 Nov 2;9(11):2397. doi: 10.3390/cells9112397.
Enterococci are the second most common Gram-positive pathogen responsible for nosocomial infections. Due to the limited number of new antibiotics that reach the medical practice and the resistance of enterococci to the current antibiotic options, passive and active immunotherapies have emerged as a potential prevention and/or treatment strategy against this opportunistic pathogen. In this review, we explore the pathogenicity of these bacteria and their interaction with the host immune response. We provide an overview of the capsular polysaccharides and surface-associated proteins that have been described as potential antigens in anti-enterococcal vaccine formulations. In addition, we describe the current status in vaccine development against enterococci and address the importance and the current advances toward the development of well-defined vaccines with broad coverage against enterococci.
肠球菌是导致医院感染的第二大常见革兰氏阳性病原体。由于进入医疗实践的新型抗生素数量有限,且肠球菌对当前的抗生素选择存在耐药性,因此被动和主动免疫疗法已成为针对这种机会性病原体的潜在预防和/或治疗策略。在这篇综述中,我们探讨了这些细菌的致病性及其与宿主免疫反应的相互作用。我们概述了已被描述为抗肠球菌疫苗制剂中潜在抗原的荚膜多糖和表面相关蛋白。此外,我们还描述了针对肠球菌的疫苗开发的现状,并讨论了开发针对肠球菌具有广泛覆盖范围的明确疫苗的重要性和当前进展。